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Introduction Hepatic encephalopathy is deﬁned as brain dysfunction caused by liver insufﬁciency and/or portosystemic
shunting. Symptoms include nonspeciﬁc cognitive impairment, personality changes and changes in consciousness. Overt
(symptomatic) hepatic encephalopathy is a common complication of cirrhosis that is associated with a poor prognosis. Patients
with hepatic encephalopathy may present to healthcare providers who do not have primary responsibility for management of
patients with cirrhosis. Therefore, we developed a series of ‘consensus points’ to provide some guidance on management.
Methods Using a modiﬁed ‘Delphi’ process, consensus statements were developed that summarize our recommendations for
the diagnosis and management of patients with hepatic encephalopathy. Points on which full consensus could not be reached
are also discussed.
Results Our recommendations emphasize the role of all healthcare providers in the identiﬁcation of cognitive impairment in
patients with cirrhosis and provide guidance on steps that might be considered to make a diagnosis of overt hepatic
encephalopathy. In addition, treatment recommendations are summarized. Minimal hepatic encephalopathy can have a
signiﬁcant impact on patients; however, in most circumstances identiﬁcation and management of minimal hepatic
encephalopathy remains the responsibility of specialists in liver diseases.
Conclusion Our opinion statements aim to deﬁne the roles and responsibilities of all healthcare providers who at times care for
patients with cirrhosis and hepatic encephalopathy. We suggest that these recommendations be considered further by
colleagues in other disciplines and hope that future guidelines consider the management of patients with cirrhosis and with a
‘suspicion’ of cognitive impairment through to a formal diagnosis of hepatic encephalopathy. Eur J Gastroenterol Hepatol
28:146–152
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Introduction
Hepatic encephalopathy (HE) is deﬁned as ‘brain dys-
function caused by liver insufﬁciency and/or portosystemic
shunting’ [1]. Symptoms of overt HE include nonspeciﬁc
cognitive impairment, personality changes and changes in
consciousness – particularly disturbance of the sleep/wake
cycle [1–3]. In more severe HE, patients may become dis-
orientated, acutely confused and suffer from agitation or
coma [1,2,4]. Minimal HE, the mildest form of HE, is
clinically undetectable and requires the use of psycho-
metric or neurophysiological testing to make a diagnosis
[1,5].
Overt HE is a common complication of cirrhosis; at
diagnosis approximately 10% of patients have HE [6,7]
and 20–40% of patients with cirrhosis will develop HE
during their disease course [8]. In a multicentre study in
Europe, of 2145 successive patients at different stages of
liver disease 21% had HE [9]. HE is also associated with a
poor prognosis; 1-year mortality in patients with HE was
64% in one population-based series [7]. Mortality may
also be correlated with HE severity [9,10]. In addition, HE
affects the patient’s quality of life [11,12] and caregiver
burden [13]. There is also accumulating evidence that after
apparent resolution of HE persistent cognitive dysfunction
may occur [14,15].
New Insights into HE (http://www.hepaticencephalo
pathy.info and http://www.HEFastFacts.info) is an edu-
cational programme developed by a Steering Committee of
hepatologists and gastroenterologists from across Europe.
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The aim of this programme is to improve the under-
standing and management of patients with HE. A series of
Needs Assessment teleconferences were undertaken in
November 2013 with 14 hepatologists and gastro-
enterologists managing patients with cirrhosis and HE.
These open-question-led interviews were designed to
identify educational needs around HE, which would
inform the ‘New Insights into HE’ educational pro-
gramme. As a result of these teleconferences, and sub-
sequent discussions with the New Insights into HE Steering
Committee and other faculty involved in developing the
educational content, it was clear that a potential barrier to
effective management of patients with HE is delay in
identiﬁcation and referral. The European Association for
the Study of the Liver (EASL) and the American
Association for the Study of Liver Diseases (AASLD)
guidelines present recommendations and options for the
diagnosis and management of patients with HE (Fig. 1) [1].
However, these guidelines reﬂect the uncertainties and
variability in management and often a lack of high-quality
evidence to support one approach over another. Therefore,
the ﬁnal recommendations present options that ‘…not all
readers may necessarily agree with…’ [1]. For the specialist
in liver diseases this guideline therefore allows for man-
agement to reﬂect personal experience and preference while
providing a framework for future developments. However,
for those healthcare providers who are not hepatologists (or
do not specialize in diseases of the liver), but have clinical
responsibility for patients with cirrhosis, no guidance is
provided to deﬁne their role in the identiﬁcation and referral
and/or management of patients with HE. To provide this
guidance, eight members of the Steering Committee devel-
oped a series of Consensus Opinion Statements to better
deﬁne the role of healthcare providers who do not specialize
in liver diseases in the management of HE. The recom-
mendations of this paper should therefore be reviewed
alongside the EASL/AASLD treatment guidelines [1], and
consideration should be given to an individual healthcare
provider’s experience and expertise.
Methods
On the basis of the results of the Needs Assessment survey
and follow on discussions, a PubMed search was under-
taken to identify additional management guidelines and
recommendations for management of HE. The MESH
term ‘hepatic encephalopathy’ combined with the sub-
headings ‘therapy’, ‘rehabilitation’, ‘diet therapy’, or ‘drug
therapy’ was used as an initial search. This was then
supplemented by a search combining the MESH term
What
Clinical signs and symptoms suggestive of HE
e.g. cognitive dysfunction, altered sleep pattern, disorientation (time and/or space), personality changes, asterixis, confusion,
sedation (coma)
e.g. complications of diabetes, intoxication (alcohol or drugs), Wernicke’s encephalopathy, electrolyte disturbances,
neuroinfections, psychiatric disorders, intracranial bleeding/stroke, medical stress
Supportive care
Rule out differential diagnoses
Overt HE
Identify and correct precipitating factors
Response
Response
No response
No response
Rifaximin
Second episode of HE No further episodes
Prevention of recurrence
First choice: nonabsorbable disaccharides (lactulose)
+ Planned discharge to include preventive care
and monitoring
GE
GE
GE
GE
Primary care
/ GP∗
Primary care
/ GP∗
Primary care
/ GP∗
Liver
specialist
Liver
specialist
Liver
specialist
Liver
specialist
Liver
specialist
∗with specialist consultation if required
Primary responsibility (who)
Acute care
clinician∗
Acute care
clinician∗
Primary care
/ GP∗
Primary care
/ GP∗
Acute care
clinician∗
Acute care
clinician∗
Treatment of overt HE event
First choice: nonabsorbable disaccharides (lactulose)
(short-term neomycin or metronidazole are alternatives)
Consider oral BCAAs or
intravenous LOLA
Albumin dialysis, embolization of spontaneous
portosystemic shunts, experimental treatment
 (not in EASL / AASLD guidelines)
GE
Liver
specialist
Acute care
clinician
Primary care
/ GP
GE
Liver
specialist
Acute care
clinician∗
Fig. 1. An overview of the latest European Association for the Study of the Liver/American Association for the Study of Liver Diseases (EASL/AASLD) treatment
guidelines for overt hepatic encephalopathy [1], and the role of different medical specialists in the implementation of these guidelines according to our
consensus recommendations (grey boxes indicate ‘optional’ involvement, if there is sufﬁcient experience and conﬁdence). BCAAs, branched chain amino
acids; GE, gastroenterologist; GP, general practitioner; HE, hepatic encephalopathy; LOLA, L-ornithine L-aspartate.
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‘hepatic encephalopathy’ and the article types ‘consensus
development conference’, ‘consensus development con-
ference, NIH’, or ‘guideline’. A total of 1146 possible
publications were identiﬁed and a manual search of this
list was then undertaken to identify publications that could
inform the development of draft statements. Because of the
paucity of suitable papers, a free text search (‘hepatic
encephalopathy’ AND (guideline* OR algorithm)) and a
MESH search (‘cognition disorders’ AND cirrhosis) were
also undertaken. These did not retrieve any additional
suitable citations.
A number of statements were then developed by a sin-
gle, nonvoting author (I.E.J.M.) that attempted to better
deﬁne the role of the general practitioner, acute care
physician, general gastroenterologist and liver specialist/
hepatologist in the management of HE. These statements
were reviewed and scored by the eight expert authors
(Panel) using a modiﬁed ‘Delphi’ process. The Delphi
process has been explained in detail elsewhere but is brieﬂy
summarized [16,17]. Each of the eight authors scored each
statement on a scale of 1–5, where 1= strongly disagree,
2=disagree, 3=neutral, 4= agree and 5= strongly agree.
Each member of the Panel was asked to provide com-
ments, if any, or points of clariﬁcation. The scores were
anonymized and collated and mean scores and ranges
from the Panel’s ﬁrst round were then recirculated to all
members of the Panel with the collated comments. Each
Panel member was invited to revise their scores in a second
round. In addition, statements with a wide range of
responses were revised, and in subsequent rounds the
Panel was again asked to provide their scores. After the
third round scores were collated to produce mean and
mode scores, as well as the range of ﬁnal scores. Using the
deﬁnition of ‘Consensus’ as no more than one individual
score being no greater than two scores from the mode, the
majority of statements approached consensus after three
rounds of voting and revision. These results were used to
develop a ‘Discussion Document’ that used points of
consensus and nonconsensus to develop the ‘Panel
Recommendations’ deﬁned below. As the ﬁnal round of
this process, the Discussion Document was reviewed and
reﬁned by teleconference, and agreement reached whether
consensus was possible, or whether the ﬁnal Panel
Recommendations should reﬂect differences in opinion or
clinical practice. These recommendations and points of
consensus or nonconsensus are described below and
summarized in Fig. 1.
Results
Delphi process
Strong levels of consensus were reached regarding the role
of gastroenterologists and liver specialists in the clinical
diagnosis of HE, with lower levels of consensus regarding
the role of the family physician. There was also consensus
that all patients with cirrhosis should be assessed, not only
those with a history of decompensation. As shown, full
consensus was not reached regarding the speciﬁc diag-
nostic test or tests that should be used, nor the treatment of
an overt HE episode. In contrast, there was general con-
sensus that secondary prophylaxis was appropriate.
During the ﬁnal teleconference, agreement was reached to
develop the ‘recommendations’ below with all members of
the Panel providing agreement. The relevant consensus
statements and level of consensus are also provided for
each recommendation.
Panel recommendations
(1) General practitioners, acute care physicians and
others, who may encounter patients with cirrhosis,
should be aware of the signs and symptoms of HE. If
these healthcare providers identify cognitive impair-
ment, or symptoms of HE, in patients with cirrhosis,
additional clinical assessment/workup may be required.
This may include specialist consultation if helpful.
All patients with cirrhosis should be assessed clinically
for overt HE by their family physician: 38% strongly
agree; 25% agree (mean score: 3.63/5).
Most patients with cirrhosis will be under appropriate
specialist care. The primary care physician plays a vital
role in the identiﬁcation of patients with liver disease
and should be aware of at-risk groups in addition to
clinical signs and symptoms. Guidelines for the
primary care provider on this are lacking. HE as a
ﬁrst presentation of cirrhosis would be unusual [7].
However, HE should be considered in the differential
diagnosis in appropriate clinical settings – for example,
the patient with risk factors for liver disease, the
patient with physical signs suggesting liver disease, or
the patient with abnormal serum liver function tests.
Unlike other decompensation events (e.g. variceal
bleeding, ascites), patients with HE may not present
to their usual specialist as a result of their symptoms
[18], and patients with prior HE are more likely to
present to their primary care provider or as an
emergency admission [13]. Therefore, it is necessary
that patients with HE not presenting to their usual
healthcare provider are identiﬁed and appropriate
treatment initiated. Although assessment of cognition
and psychiatric symptoms is relatively simple, making
a deﬁnitive diagnosis of HE is more difﬁcult and HE
remains a diagnosis of exclusion [1]. Symptoms of HE
are relatively nonspeciﬁc (Table 1), which can lead to
challenges in making a formal diagnosis of HE.
Therefore, providers should be ready to consider HE
as a cause of cognitive dysfunction and symptoms in
patients with cirrhosis, and either work up the patient
to make a formal diagnosis or, if necessary, be
prepared to refer such patients to specialist care for
further assessment. This prompt workup and/or
referral should allow for early initiation of appropriate
management, which might reduce the risk of hospita-
lization and thus reduce healthcare costs [19].
(2) The lead clinician caring for patients with cirrhosis
(gastroenterologist or liver specialist) should formally
assess all patients for signs and symptoms of HE.
All patients with cirrhosis should be assessed clinically
for overt HE by their gastroenterologist: 63% strongly
agree; 25% agree (mean score: 4.5/5).
All patients with cirrhosis should be assessed clinically
for overt HE by their liver specialist: 75% strongly
agree; 25% agree (mean score: 4.75/5).
Although the general practitioner or acute care
physician or other healthcare provider encountering
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patients with cirrhosis and cognitive impairment
should have a low ‘threshold’ for suspecting HE as a
possible cause, we believe that it is the responsibility of
the lead clinician (gastroenterologist or liver specialist)
to routinely assess patients with cirrhosis for symp-
toms of HE. According to current guidelines this may
involve clinical assessment and/or psychometric test-
ing [1]. As stated below (point 3), the selection of
additional psychometric testing remains a matter of
personal experience and availability. Routine formal
assessment will facilitate early identiﬁcation of symp-
toms of HE, and therefore initiation of appropriate
management.
(3) Assessment for overt HE should principally be by
clinical evaluation, with use of additional testing as
required on an individual basis (and according to
availability).
The assessment of overt HE outside a liver unit should
be by clinical evaluation only: 25% strongly agree;
50% agree (mean score: 3.75/5).
Only near consensus was reached for this statement as
one author strongly felt that even outside the liver unit
additional testing beyond clinical assessment was
necessary. However, on further discussion it was
agreed that for many healthcare providers the facilities
are not available to undertake additional tests.
Therefore, the ﬁnal statement above, which allows
for additional testing ‘if available’, was agreed upon.
The EASL/AASLD guidelines state that overt HE
is primarily a clinical diagnosis (Table 1) [1].
Psychometric and neurophysiological tests do not
differentiate HE from other causes of cognitive
dysfunction, and differential diagnoses include renal
dysfunction, hyponatraemia, diabetes, sepsis, alcohol
withdrawal and Wernicke’s encephalopathy [1].
However, psychometric, psychophysical and
neurophysiological tests can have some value in
supporting the clinical diagnosis of lower grades of
overt HE, in addition to their use to detect minimal
HE. These include simple paper and pencil tests
(including the Psychometric Hepatic Encephalopathy
Score test) as well as more sophisticated psychometric
tests including the Inhibitory Control Test and
Repeated Battery for Assessment of Neurological
State, neurophysiological testing by electroencephalo-
gram, or psychophysical testing – for example, the
Critical Flicker Frequency [1]. Full consensus on the
use of a speciﬁc test or tests could not be reached,
reﬂecting differences in availability and clinical opi-
nion. It should be noted that not all of the available
tests are fully validated and many require administra-
tion by a trained examiner. The results of several of
these including the Inhibitory Control Test and
Psychometric Hepatic Encephalopathy Score test, can
be affected by age, educational status and training
effects, and for many tests validated ‘normals’ are not
available for all countries/languages and populations.
The availability of equipment for these tests varies,
and in many centres pencil and paper tests are used
and remain valuable. However, if available, the
Critical Flicker Frequency test was felt by some
authors to have several advantages, including lack of
training effect, educational status, and age, and
avoidance of interexaminer variability [20,21].
(4) For all patients with HE, consideration should usually
be given for referral to a liver unit or physician who
specializes in liver disease.
All patients with overt HE should be referred to a liver
unit: 50% strongly agree; 38% agree (mean score:
4.38/5).
HE is a decompensation event and all healthcare
providers managing patients with a diagnosis of HE
should consider whether the patient should be referred
to a liver specialist. Although policies vary with
respect to wait-listing patients with HE and a number
of allocation scoring systems have been proposed [22],
further assessment of patients with HE is warranted as
they may be eligible for assessment for liver trans-
plantation [1].
(5) All patients with overt HE should be treated (includ-
ing checking for precipitants).
All patients with HE should be treated: 75% strongly
agree; 25% agree (mean score: 4.75/5).
The most important step in the management of HE is
evaluation for precipitants (Table 2) [1,23] and
Table 1. Signs and symptoms of hepatic encephalopathy (modiﬁed
from EASL/AASLD, Hepatic encephalopathy in chronic liver disease:
2014 practice guideline by the European Association for the Study of the
Liver and the American Association for the Study of Liver Diseases.
Journal of Hepatology 61, 642–659, Elsevier, © 2014 [1])
Grades of HE
(West Haven
Criteria)
Minimal Psychometric or neuropsychological alterations of tests
exploring psychomotor speed/executive functions or
neurophysiological alterations without clinical evidence of
mental change
1 Trivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impairment of addition or subtraction
Altered sleep rhythm
2 Lethargy or apathy
Disorientation for time
Obvious personality change
Inappropriate behaviour
Dyspraxia
Asterixis
3 Somnolence or semistupor
Responsive to stimuli
Confused
Disorientation
Bizarre behaviour
4 Coma
HE, hepatic encephalopathy.
Table 2. Precipitants implicated in the development of overt hepatic
encephalopathy [1,23]
Infections
GI bleeding
Over-diuresis
Vomiting/diarrhoea
Electrolyte disorder
Constipation
Surgery
TIPS
Sedative/narcotic drug use (nonadherence to secondary prophylaxis for HE)
GI, gastrointestinal; HE, hepatic encephalopathy; TIPS, transjugular intrahepatic
portosystemic shunt.
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appropriate intervention. In addition, all patients with
a diagnosis of overt HE should be treated [1]. The
most commonly used treatments are nonabsorbable
disaccharides [1]. A meta-analysis indicated that
lactulose or lactitol therapy resulted in clinical
improvement, although there was no effect on
mortality [24]. Although the same meta-analysis
reported that nonabsorbable disaccharides were infer-
ior to short-course antibiotic therapy [24], lactulose is
the usual ‘ﬁrst choice’ treatment for overt HE [1].
Antibiotics are, however, commonly used, whereas
other therapies available in some countries include
oral branched chain amino acids [25] and intravenous
L-ornithine L-aspartate (LOLA) [26]. Other treatment
options specialists may consider include albumin
dialysis [27] and embolization of large spontaneous
portal–systemic shunts [28], although these are not
part of the EASL/AASLD recommendations [1]. If
helpful, advice on treatment should be sought from a
specialist in liver diseases, particularly for more severe
cases, and/or those for whom a nonstandard therapy is
being considered.
(6) After recovery/improvement of HE symptoms, sec-
ondary prophylaxis should be considered in all
patients.
After recovery/improvement of overt HE, patients
should receive secondary prophylaxis: 83% strongly
agree; 16% agree (mean score: 4.83/5).
Prior HE is associated with an increased risk for
subsequent episodes [8,9]. In one study ∼ 50% of
patients with at least one prior HE event (median 1)
suffered recurrence within 1 year [29], and in another,
46% of those with at least two prior events suffered
recurrence within 6 months [30]. Therefore, it is
appropriate to offer secondary prophylaxis to reduce
recurrence in most, if not all, patients recovering from
an episode of HE [1]. Secondary prophylaxis should
be initiated by the clinician managing an episode of
HE, with advice from a gastroenterologist or specialist
in liver disease if helpful.
In patients with a median of one prior episode,
lactulose was associated with a signiﬁcant reduction in
the risk for recurrence over a median 14 months’
follow-up [27]. Patients receiving lactulose should
have the dose adjusted so that there are two or three
bowel movements daily but without diarrhoea [1]. In
patients with at least two prior episodes of HE in the
previous 6 months (the majority of whom were
receiving lactulose), rifaximin-α (rifaximin) 550mg
twice daily was associated with a signiﬁcant reduction
in the risk for recurrent HE over 6 months and a
reduction in the risk for HE-related hospitalization
[28]. The EASL/AASLD guidelines suggest rifaximin
550mg twice daily add-on to lactulose after the
second episode of HE [1]. It may also be appropriate
to consider rifaximin monotherapy in patients intol-
erant to lactulose despite patient education, and dose
adjustment to achieve two or three bowel movements
each day.
A number of other therapies used for secondary
prophylaxis are not included in the EASL/AASLD
guidelines [1] but were felt by some authors to have a
role. Full consensus could not be reached on these
treatments, partly because of differences in availability
and clinical experience. These included laxatives [31],
branched chain amino acids [25,32,33] and LOLA
[26,34,35]. For patients with hyperammonaemia and
HE, LOLA was felt to be particularly helpful by one
author, although only intravenous LOLA was
reported by the EASL/AASLD guidelines as being
effective for the treatment of HE episodes but not for
secondary prophylaxis [1]. There was also experience
of using oral branched chain amino acids in patients
with chronic HE who were protein intolerant, as
recommended by the International Society for Hepatic
Encephalopathy and Nitrogen Metabolism (ISHEN)
guidelines on nutrition [36]. Patients receiving sec-
ondary prophylaxis should be encouraged to remain
on therapy to maximize the beneﬁts of treatment. It is
the responsibility of all healthcare professionals who
encounter patients with cirrhosis and HE to encourage
compliance with therapy.
(7) Liver specialists may assess patients with cirrhosis for
minimal HE; other healthcare professionals caring for
patients with cirrhosis should not be expected to
routinely assess patients for minimal HE.
Patients with cirrhosis should be assessed for minimal
HE by their gastroenterologist: 38% strongly agree;
38% agree (mean score: 4.13/5).
Patients with cirrhosis should be assessed for minimal
HE by their liver specialist: 88% strongly agree; 13%
agree (mean score: 4.88/5).
Substantial expertise is required to make a diagnosis
of minimal HE and the diagnosis is deﬁned by the test
used. In addition, there are no therapies with a speciﬁc
approval for its treatment. Therefore, it may be
reasonable to expect that diagnosis and management
of minimal HE should remain the responsibility of
liver specialists. Although treatment for minimal HE
has been shown to improve cognitive test score and
quality of life [37–39], it is not yet possible to conﬁrm
beneﬁts in terms of reduced episodes of overt HE or
other clinical outcomes. As a result, there is no
agreement over potential treatment strategies, includ-
ing the optimal duration of therapy [1].
It is appropriate for those healthcare providers caring
for patients with cirrhosis, who have the expertise and
experience, to utilize psychometric or neurophysiolo-
gical tests on a case-by-case basis if this will help
clinical decision making. This reﬂects the EASL/
AASLD guidelines, which suggest that consideration
be given to testing patients for minimal HE and
providing counselling in some circumstances – for
example, potential consequences on driving, ﬂying,
train drivers, or operating machinery [1].
(8) If diagnosed, consideration should be given to
treatment of patients with minimal HE.
All patients with a diagnosis of minimal HE should be
treated: 38% strongly agree; 38% agree (mean score:
4.13/5).
If a diagnosis of minimal HE has been made it is
reasonable to consider treatment, accepting the
caveats above regarding uncertainties surrounding
the endpoints of treatment and lack of licensed
therapies. Such a decision should be taken in
consultation with a specialist in liver diseases.
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Discussion
The recently published guidelines from the EASL/AASLD
provide a framework for the diagnosis and management of
patients with HE [1]. Our opinion statements aim to deﬁne
the role and responsibilities of all those healthcare provi-
ders who at times care for patients with cirrhosis and HE
(Fig. 1). Although developed before the EASL/AASLD
guidelines were published, the expert consensus opinion
statements discussed here do not differ signiﬁcantly from
these guidelines.
In developing these statements we have acknowledged
that making a deﬁnitive diagnosis of HE can be difﬁcult.
However, it is possible for all those healthcare providers
who encounter patients with cirrhosis to identify cogni-
tive impairment and be aware of HE in terms of the
impact on patients. For those healthcare providers who
do not have primary responsibility for management of
patients with cirrhosis we believe that it is reasonable
that patients with suspected HE are referred to their
gastroenterologist or liver specialist. It is then the
responsibility of the primary provider (gastroenterologist
or liver specialist) to ensure that appropriate clinical
assessments are undertaken to make a diagnosis of overt
HE. The use of psychometric and neurophysiological
tests is essential to identify minimal HE, but the authors
also felt they can be useful in the assessment of lower
grades of overt HE. Gastroenterologists who have
appropriate training and facilities/equipment should be
prepared to supplement clinical assessment with such
tests. If appropriate facilities or trained staff are not
available, discussion with a liver specialist or liver unit
should be considered. As HE is a decompensation event,
such a discussion can be helpful to allow prompt con-
sideration of whether the patient should be evaluated for
liver transplantation.
Speciﬁc therapy for overt HE episodes includes sup-
portive care, treatment of underlying precipitants, and
initiation of speciﬁc therapy; ﬁrst-line choices are non-
absorbable disaccharides or short-course antibiotics [1].
All patients recovering from an acute episode of overt HE
should also receive secondary prophylaxis to reduce the
risk of recurrence; the evidence-based choices include
nonabsorbable disaccharides and/or rifaximin [1].
Appropriate therapy can reduce the duration of admission
and reduce the risk of subsequent readmission. However,
to maximize the beneﬁts from therapy, early diagnosis is
essential to allow prompt initiation of recommended
treatment.
We recommend that our conclusions and recommen-
dations be considered further by our colleagues in gas-
troenterology and hepatology and those in other
disciplines and hope that these recommendations assist in
the development of regional/national cross-speciality
guidelines to improve the identiﬁcation and triage of
patients who may have HE and facilitate appropriate
management. We also hope that future guidelines consider
the management of patients with HE from initial ‘suspi-
cion’ of cognitive impairment, which may be by a clinician
or healthcare provider not routinely responsible for man-
agement of an individual’s liver disease.
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